Helping Patients Achieve Their Vision Goals
We support patients throughout every step of the SING IMT patient journey, including diagnosis, evaluation, implantation, and rehabilitation.
The SING IMT is approved for late-stage AMD patients who are 55 years of age or older CE Referenced Countries and is not currently FDA Approved in the United States. Because AMD is a progressive disease, over time, patients have adapted with the loss of vision in the central field of vision. Before receiving the SING IMT, patients must understand the possible and realistic outcomes post-op and commit to working with their ophthalmological team to use visual techniques and exercises to maximize the effectiveness of SING IMT.
The telescopic implant is not a cure for late-stage age-related macular degeneration (AMD). It will not return your vision to the level you had before your AMD, nor will it completely make up for your vision loss. The goal is that you can see more in your central field of vision and that things come back to your life that you love to see and do. Your ophthalmologist will explain the risks and benefits of the telescopic implant as well as the short and long-term risks of the surgery. It is important that you work closely with your team of specialists so that you can make the most of your new eyesight after the telescopic implant procedure.